Generali Investments Towarzystwo Funduszy Inwestycyjnych Intellia Therapeutics, Inc. Transaction History
Generali Investments Towarzystwo Funduszy Inwestycyjnych
- $172 Billion
- Q4 2024
A detailed history of Generali Investments Towarzystwo Funduszy Inwestycyjnych transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Generali Investments Towarzystwo Funduszy Inwestycyjnych holds 62,000 shares of NTLA stock, worth $596,440. This represents 0.42% of its overall portfolio holdings.
Number of Shares
62,000
Previous 35,000
77.14%
Holding current value
$596,440
Previous $719 Million
0.51%
% of portfolio
0.42%
Previous 0.46%
Shares
7 transactions
Others Institutions Holding NTLA
# of Institutions
317Shares Held
90.9MCall Options Held
442KPut Options Held
880K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.5MShares$121 Million1.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.63MShares$92.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$92.3 Million0.0% of portfolio
-
State Street Corp Boston, MA5.14MShares$49.5 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.95MShares$47.6 Million3.75% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $731M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...